IRD Stock Forecast: Opus Genetics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Opus Genetics, Inc. is $14. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Opus Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (95): The shares have been drifting up relative to others.
Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IRD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IRD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $14 |
| 11 Nov 2026 | RBC Capital | Maintains | Outperform | $9.00 → $11 |
| 22 Oct 2026 | Chardan Capital | Maintains | Buy | $16 |
| 16 Oct 2026 | Citizens | Reiterates | Market Outperform | $17 |
| 6 Oct 2026 | Jones Trading | Maintains | Buy | — |
| 2 Oct 2026 | Chardan Capital | Maintains | Buy | $16 |
| 10 Sept 2026 | Wedbush | Maintains | Outperform | $10 → $13 |
| 9 Sept 2026 | BTIG | Reiterates | Buy | $12 |
| 9 Sept 2026 | Chardan Capital | Maintains | Buy | $13 → $16 |
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 9 Sept 2026 | Oppenheimer | Maintains | Outperform | $10 → $20 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $10 → $9.00 |
| 29 July 2026 | TD Cowen | Initiates | Buy | — |
| 6 July 2026 | BTIG | Reiterates | Buy | $12 |
| 6 July 2026 | Chardan Capital | Maintains | Buy | $13 |
| 18 June 2026 | Chardan Capital | Maintains | Buy | — |
| 17 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 June 2026 | BTIG | Reiterates | Buy | — |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | — |
| 4 June 2026 | Guggenheim | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IRD.
This page is one stock. Monday covers all of them.
IRD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IRD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Opus Genetics, Inc. returned +106.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IRD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 48.7×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 5% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −58.5%
- Dividend yield
- —
Higher than 6% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Opus Genetics, Inc. has a market value of $385.7M and an enterprise value of $332.6M.
Revenue in the twelve months to 30 June 2026: $9.9M. The latest quarter shrank 73.8% year on year.
Net income over the same four quarters: −$107.6M, a −1091.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$40.7M.
Opus Genetics, Inc. spent $149K on share buybacks in the twelve months to 30 June 2026.
Opus Genetics, Inc. employs 27 people — $365K of revenue per employee.
Data provided by Twelve Data
IRD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IRD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Opus Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IRD
What is the IRD stock price forecast for 2026-2027?
The median 12-month analyst price target for Opus Genetics, Inc. is $14, with estimates ranging from $8 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IRD stock a buy right now?
Of the 18 analysts covering Opus Genetics, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Opus Genetics, Inc. 39 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IRD?
As at 21 Nov 2026, Opus Genetics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).
Will IRD stock go up?
No one can know that. What the data says: the median 12-month target from 18 analysts is $14, and Ticker Nerd's factor model ranks Opus Genetics, Inc. 39 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IRD stock forecast for 2030?
No analyst covering Opus Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $20 over the next 12 months.
How has IRD stock performed over the past year?
Opus Genetics, Inc. returned +106.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Opus Genetics, Inc. do?
Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases.
About Opus Genetics, Inc.
Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases. Its current pipeline includes investigational candidates such as OPGx-LCA5 and OPGx-BEST1, along with other ophthalmology-focused programs targeting specific genetic retinal conditions. Opus Genetics serves the broader vision-care market through research, development, and commercialization efforts centered on restoring or preserving sight in patients with unmet medical needs. The company is headquartered in Durham, North Carolina.
CEO Dr. George Magrath M.B.A., M.D., M.S. · 27 employees · United States · https://opusgtx.com